Evommune EVMN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 53.7%— | 52.7%— | 55.9%— | 55.2%— | —— | |
| Operating margin | -30.7%— | -21.2%— | -5.9%— | -8.3%— | —— | |
| Liquidity | ||||||
| Current ratio | 1.2×— | 0.9×+0.4× | 0.7×— | —— | —— | |
| Per Share | ||||||
| Book value per share | -$0.23-1,142% | $0.02+202% | $0.08+320% | —— | $0.02— | |
| Valuation | ||||||
| Market capitalization | $848.59M+39.5% | $539.69M— | —— | —— | —— | |
| Price / sales | 127.3×— | 81.6×— | —— | —— | —— |
Questions, answered.
- What are Evommune 's profit margins?
- Evommune (EVMN) runs a 53.7% gross margin and a -30.7% operating margin, with a -90.1% net margin.
- Where do Evommune 's ratios come from?
- Every ratio is computed from Evommune 's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
